These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 2033654)

  • 21. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2.
    Bodmer S; Strommer K; Frei K; Siepl C; de Tribolet N; Heid I; Fontana A
    J Immunol; 1989 Nov; 143(10):3222-9. PubMed ID: 2809198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of recombinant human transforming growth factor-beta 1 or/and interleukin-6 on growth inhibition and proto-oncogene c-myc expression in human leukemia cells.
    Feng R; Shen S; Hui H; Jin M
    Chin Med J (Engl); 1997 Nov; 110(11):847-50. PubMed ID: 9772416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential effects of the Ski-interacting protein (SKIP) on differentiation induced by transforming growth factor-beta1 and bone morphogenetic protein-2 in C2C12 cells.
    Figueroa JD; Hayman MJ
    Exp Cell Res; 2004 Jun; 296(2):163-72. PubMed ID: 15149847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of vinblastine, colchicine, and verapamil on rhodamine 123 accumulation in human P-glycoprotein-positive leukemia cells.
    Lautier D; Canitrot Y; Salmon JM
    Anticancer Res; 1994; 14(6B):2589-95. PubMed ID: 7872686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preliminary studies on phenothiazine-mediated reversal of multidrug resistance in mouse lymphoma and COLO 320 cells.
    Pajak B; Molnar J; Engi H; Orzechowski A
    In Vivo; 2005; 19(6):1101-4. PubMed ID: 16277030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different signals mediate transforming growth factor-beta 1-induced growth inhibition and extracellular matrix production in prostatic carcinoma cells.
    Franzén P; Ichijo H; Miyazono K
    Exp Cell Res; 1993 Jul; 207(1):1-7. PubMed ID: 7686495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide.
    Ferrari N; Pfeffer U; Dell'Eva R; Ambrosini C; Noonan DM; Albini A
    Clin Cancer Res; 2005 Jun; 11(12):4610-9. PubMed ID: 15958647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of apoptosis by transforming growth factor beta 1 in glioma and trigeminal neurinoma cells.
    Marushige K; Marushige Y
    Anticancer Res; 1994; 14(6B):2419-24. PubMed ID: 7872662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transport mechanism of DIAM 3, a new anticancer drug, in human glioblastoma (U 251) cells in culture.
    Khan NA; Masson I; Darcel F; Quemener V; Labarre JF; Moulinoux JP
    Biochem Pharmacol; 1990 Jun; 39(12):2057-60. PubMed ID: 2353945
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes--first experience with their reversal.
    Nüssler V; Pelka-Fleischer R; Zwierzina H; Nerl C; Beckert B; Gullis E; Gieseler F; Bock S; Bartl R; Petrides PE
    Ann Hematol; 1994; 69 Suppl 1():S25-9. PubMed ID: 7914749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High dose chemotherapy for the treatment of malignant brain tumors.
    Petersdorf SH; Livingston RB
    J Neurooncol; 1994; 20(2):155-63. PubMed ID: 7807192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transforming growth factors type beta inhibit multidrug transport in rat astrocyte cell lines.
    Schluesener HJ
    Autoimmunity; 1991; 9(3):269-75. PubMed ID: 1685677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spontaneous multidrug transport in human glioma cells is regulated by transforming growth factors type beta.
    Schluesener HJ; Meyermann R
    Acta Neuropathol; 1991; 81(6):641-8. PubMed ID: 1679277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux.
    Minderman H; Vanhoefer U; Toth K; Yin MB; Minderman MD; Wrzosek C; Slovak ML; Rustum YM
    Cytometry; 1996 Sep; 25(1):14-20. PubMed ID: 8875050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Transfection of recombinant bone morphogenetic protein-7 expressing plasmid into cultured human renal tubular epithelial cells attenuates the extracellular matrix accumulation induced by transforming growth factor-beta].
    Li Y; Chen N; Yu HJ; Dong XP; Huang QH
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):544-8. PubMed ID: 16681885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multidrug transport in human glioblastoma cells is inhibited by transforming growth factors type beta 1, beta 2, and beta 1.2.
    Schluesener HJ
    J Neurosci Res; 1991 Feb; 28(2):310-4. PubMed ID: 2033654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microglia-derived TGF-beta as an important regulator of glioblastoma invasion--an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor.
    Wesolowska A; Kwiatkowska A; Slomnicki L; Dembinski M; Master A; Sliwa M; Franciszkiewicz K; Chouaib S; Kaminska B
    Oncogene; 2008 Feb; 27(7):918-30. PubMed ID: 17684491
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.